^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Imfinzi (durvalumab)

    i
    Other names: MEDI4736, MEDI-4736, MEDI 4736
    Company:
    AstraZeneca
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    1d
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=330, Recruiting, I-Mab Biopharma US Limited | N=168 --> 330 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    Opdivo (nivolumab) • Imfinzi (durvalumab) • givastomig (TJ-CD4B)
    2d
    Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy (clinicaltrials.gov)
    P2, N=13, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    EGFR mutation • ALK mutation
    |
    Imfinzi (durvalumab)
    2d
    Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date • Tumor mutational burden • IO biomarker
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MSH6 (MutS homolog 6)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    2d
    REFMAL 412: Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=56, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    |
    Imfinzi (durvalumab) • adavosertib (AZD1775)
    2d
    NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Nov 2026
    Trial completion date • Platinum resistant
    |
    PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    3d
    CCTG BR34: Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC (clinicaltrials.gov)
    P2, N=301, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • NKX2-1 (NK2 Homeobox 1) • TP63 (Tumor protein 63)
    |
    EGFR mutation • ALK fusion
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    4d
    MYSTIC: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=1118, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • paclitaxel • Imjudo (tremelimumab-actl) • pemetrexed
    7d
    Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) (clinicaltrials.gov)
    P3, N=810, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> May 2027
    Trial completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine
    7d
    PHOX: Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=99, Recruiting, Mayo Clinic | Trial completion date: Nov 2026 --> May 2031 | Trial primary completion date: May 2026 --> May 2031
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • docetaxel • oxaliplatin • leucovorin calcium • fluorouracil topical
    7d
    Successful Management of Suspected Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in BRAF-Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors: A Case Report. (PubMed, Cancer Rep (Hoboken))
    We report a rare case of cholangiocarcinoma with suspected EBV-associated HLH that developed after sequential therapy with an ICI and BRAF/MEK inhibitors. Clinicians should consider HLH as a differential diagnosis in patients with a history of ICI therapy who present with severe unexplained inflammation or shock. Prompt diagnosis and multidisciplinary management are crucial to prevent death.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    IL2 (Interleukin 2)
    |
    BRAF V600E • BRAF mutation • BRAF V600
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine
    7d
    DOVACC: Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer (clinicaltrials.gov)
    P2, N=188, Active, not recruiting, Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2026 --> May 2026
    Enrollment closed • Trial primary completion date
    |
    Myriad myChoice® CDx • TruSight Oncology 500 HRD Assay
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • UV1